Dai­ichi says it’s ready to change the stan­dard of care for acute myeloid leukemia — but it’s a work in progress

Close to 4 years ago, Dai­ichi Sankyo swooped in to buy lit­tle San Diego-based Am­bit Bio­sciences for up to $410 mil­lion — $315 mil­lion of that …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.